N4 Pharma plc (N4P) ORD GBP0.004
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
N4 Pharma reports positive progress with SRI collaboration
20 August 2024 10:10
(Sharecast News) - N4 Pharma, a specialist pharmaceutical company focused on the development of Nuvec, a novel delivery system for cancer treatments, gene therapy, and vaccines, updated the market on its...
-
N4 Pharma shares tank after £0.6m fundraise
7 June 2024 11:06
(Sharecast News) - Shares in small-cap pharma group N4 Pharma sank on Friday after the company announced a share placing and subscription to raise £630,000.
-
N4 Pharma shares jump on latest Nuvec developments
15 February 2024 13:17
(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.
-
N4 Pharma's Nuvec granted patent in India
19 January 2024 13:00
(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding...
-
N4 Pharma subsidiary agrees work programme for glaucoma treatment
16 January 2024 14:05
(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for...
-
N4 Pharma reports progress in Nuvec clinical research
8 January 2024 12:30
(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.
-
N4 Pharma upbeat on recent Nuvec developments
18 December 2023 11:17
(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.
-
N4 Pharma posts optimistic Nuvec research update
7 December 2023 13:20
(Sharecast News) - N4 Pharma, a specialist pharmaceutical company focused on developing the Nuvec delivery system for cancer treatments and vaccines, issued an optimistic update on its ongoing in-vitro siRNA...
-
N4 Pharma picks up controlling interest in Nanogenics
28 September 2023 13:28
(Sharecast News) - Pharmaceutical firm N4 Pharma announced the acquisition of a controlling interest in Nanogenics on Thursday.
-
N4 Pharma reports progress with siRNA work
18 April 2023 13:13
(Sharecast News) - N4 Pharma updated the market on its ongoing research work on gene-silencing technology siRNA on Tuesday.
-
N4 Pharma shares tumble following placing, broker offer announcement
18 November 2022 08:11
(Sharecast News) - Shares in pharmaceutical company N4 Pharma tumbled on Friday after the group said it had raised £1.0m via the placing of 50.0m new ordinary shares of 0.4p each and detailed a broker offer...
-
N4 Pharma reports success in recent 'Nuvec' testing
4 October 2022 13:32
(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced success in its in-vitro testing of its 'Nuvec' drug delivery system on Tuesday, loaded with two small interfering RNA...
Company announcements Announcements
-
Interim Results
24 September 2024 07:00
N4 Pharma
-
SRI Research Update
17 September 2024 08:04
N4 Pharma
-
Change of Auditor
23 August 2024 08:30
N4 Pharma
-
SRI Research Update
20 August 2024 07:00
N4 Pharma
-
Nanogenics Update
3 July 2024 07:00
N4 Pharma
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.